Future classes of hepatitis C virus therapeutic agents
Related Experiment Video
Updated: May 17, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Jennifer Y Chen1, Raymond T Chung
1GI Unit, Massachusetts General Hospital, GRJ724, 55 Fruit Street, Boston, MA 02114, USA.
Abstract:
Recent advances in understanding of the molecular characteristics of the hepatitis C virus have led to the development of novel antiviral therapeutics. Direct-acting antivirals are designed to inhibit viral targets, whereas host-targeted antivirals block host factors that are used by the virus for its own life cycle. The rapid development of agents in multiple classes has led to the promise of shorter therapy duration, an improved side effect profile, and eventually interferon-sparing regimens. This article reviews novel hepatitis C virus therapeutics in development, including mechanism of action, efficacy, and adverse effects.
Related Concept Videos
Hepatitis
Inhibitors of Viral Protein Synthesis
Viral Hepatitis I: Introduction
Retrovirus Life Cycles
Microorganisms in Medicine and Therapeutics
Subviral Agents

